Drugs / THU
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04055818 | Jan 2020 → Oct 2026 expected | sickle cell disease | EpiDestiny, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | THU | “Oral 250 mg THU and 5 mg decitabine Once per week” NCT04055818 ↗ |
| Route | Oral | “Oral 250 mg THU and 5 mg decitabine Once per week” NCT04055818 ↗ |